Population Pharmacokinetics and Dose Optimization Based on Renal Function of Rivaroxaban in Thai Patients with Non-Valvular Atrial Fibrillation

• Үндсэн зохиолчид: Noppaket Singkham (Зохиогч), Arintaya Phrommintikul (Зохиогч), Phongsathon Pacharasupa (Зохиогч), Lalita Norasetthada (Зохиогч), Siriluck Gunaparn (Зохиогч), Narawudt Prasertwitayakij (Зохиогч), Wanwarang Wongcharoen (Зохиогч), Baralee Punyawudho (Зохиогч)
• Формат: Ном
• Хэвлэсэн: MDPI AG, 2022-08-01T00:00:00Z.
• Нөхцлүүд: article
• Онлайн хандалт: Connect to this object online.

Low-dose rivaroxaban has been used in Asian patients with direct oral anticoagulants (DOACs) eligible for atrial fibrillation (AF). However, there are few pharmacokinetic (PK) data in Thai patients to support precise dosing. This study aimed to develop a population PK model and determine the optimal...